EMBLAC Stock Overview
Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Embla Medical hf. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 29.60 |
| 52 Week High | DKK 0 |
| 52 Week Low | DKK 0 |
| Beta | 0.67 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -38.78% |
| Change since IPO | 202.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMBLAC | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 7.7% | -0.4% |
| 1Y | n/a | -2.1% | 5.6% |
Return vs Industry: Insufficient data to determine how EMBLAC performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how EMBLAC performed against the UK Market.
Price Volatility
| EMBLAC volatility | |
|---|---|
| EMBLAC Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EMBLAC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EMBLAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 4,000 | Sveinn Solvason | www.emblamedical.com |
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated.
Embla Medical hf. Fundamentals Summary
| EMBLAC fundamental statistics | |
|---|---|
| Market cap | DKK 13.15b |
| Earnings (TTM) | DKK 408.09m |
| Revenue (TTM) | DKK 5.48b |
32.2x
P/E Ratio2.4x
P/S RatioIs EMBLAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBLAC income statement (TTM) | |
|---|---|
| Revenue | US$819.70m |
| Cost of Revenue | US$313.15m |
| Gross Profit | US$506.55m |
| Other Expenses | US$445.45m |
| Earnings | US$61.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 61.80% |
| Net Profit Margin | 7.45% |
| Debt/Equity Ratio | 54.3% |
How did EMBLAC perform over the long term?
See historical performance and comparison